Articles Referencing BMRN

Benzinga

Mid-Day Market Update: Markets Turn Mixed, Colonial Properties Gains On Acquisition News

Midway through trading Monday, the Dow traded up 0.38 percent to 15,172.55, while the NASDAQ fell 0.85 percent to 3,426.44. The S&P was also down, dropping 0.19 percent to 1,627.58. ... Read >>

Benzinga

Mid-Morning Market Update: Markets Rise, Cracker Barrel Posts Upbeat Earnings

Following the market opening Monday, the Dow traded up 0.69 percent to 15,220.16, while the NASDAQ rose 0.12 percent to 3,460.18. The S&P was also up, gaining 0.38 percent to 1,636.87. ... Read >>

Zacks.com

BioMarin Widens Loss, Maintains View - Analyst Blog

BioMarin Pharmaceutical Inc. 's ( BMRN ) first quarter 2013 loss of 31 cents per share was wider than the Zacks Consensus Estimate of a loss of 28 cents per share and the year-ago loss... Read >>

Zacks.com

BioMarin Attains 52-Week High - Analyst Blog

Shares of BioMarin Pharmaceutical Inc. ( BMRN ) ended the trading session on Apr 10, 2013 by reaching its 52-week high of $64.27. The company is expected to report its first quarter... Read >>

Zacks.com

BioMarin Files CTA for BMN-190 - Analyst Blog

BioMarin Pharmaceutical Inc. ( BMRN ) recently submitted a Clinical Trial Application (CTA) with the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK for... Read >>

Zacks.com

BMRN Seeks US Approval of Vimizim - Analyst Blog

BioMarin Pharmaceutical Inc. ( BMRN ) recently submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Vimizim (BMN-110, elosulfase alfa). BioMarin... Read >>

Zacks.com

Data on BioMarin's BMN-701 - Analyst Blog

BioMarin Pharmaceutical Inc. ( BMRN ) recently announced positive results on BMN-701 from the phase I/II study, POM-001. BMN-701 is a fusion protein of insulin-like growth factor 2 and acid... Read >>

David Moenning

Regeneron Pharmaceuticals Inc (REGN): Today's Most Compelling Buy

  SoTM Bull's Eye Report - Today's Most Compelling Buy Thursday, March 14, 2013 At StateoftheMarkets.com , we strive to "own the best and ignore the... Read >>

Zacks.com

BioMarin Reports Wider Loss - Analyst Blog

BioMarin Pharmaceutical Inc. 's ( BMRN ) fourth quarter 2012 loss of 43 cents per share was wider than the Zacks Consensus Estimate of a loss of 27 cents per share and the year-ago loss... Read >>

NASDAQ.com News

After-Hours Earnings Report for February 21, 2013 : AIG, HPQ, PSA, NEM, INTU, SWN, COG, JWN, SBAC, MHK, BMRN, TS

The following companies are expected to report earnings after hours on 02/21/2013. Visit our Earnings Calendar for a full list of expected earnings releases. American International Group,... Read >>

Zacks.com

Positive Data from BMRN's PKU-016 - Analyst Blog

BioMarin Pharmaceutical Inc. ( BMRN ) recently announced positive results from the PKU-016 ASCEND study. This is the largest randomized controlled study evaluating the safety... Read >>

Zacks.com

BioMarin Takes Over Zacharon - Analyst Blog

BioMarin Pharmaceutical Inc. ( BMRN ) recently acquired privately held biotechnology company, Zacharon Pharmaceuticals, which develops small molecules targeting pathways of glycan and... Read >>

GuruFocus

Weekly Top Insider Sells? AAPL, GILD, BMRN, and PCLN

According to GuruFocus Insider Data , these are the largest insider sells during the past week. The overall trend of insiders is illustrated in the chart below: Apple Inc. ( AAPL ):... Read >>

NASDAQ.com News

Pre-Market Most Active for Nov 5, 2012 : BAC, QQQ, AAPL, BMRN, GFA, BHP, FB, UBS, RIG, NOK, ZNGA, INTC

The NASDAQ 100 Pre-Market Indicator is up 40.45 to 2,696.73. The total Pre-Market volume is currently 2,926,402 shares traded. The following are the most active stocks for the pre-market... Read >>

David Sterman

4 Biotech Stocks Ready to Explode

When it comes to investing biotech stocks, it's wise to focus on companies that have completed much of their drug development work. The closer a company gets to the finish line in... Read >>

Displaying 1-15 of 18
<< first < previous 1 2 next > last >>